KR20050105164A - Improved syntheton sythesis - Google Patents
Improved syntheton sythesis Download PDFInfo
- Publication number
- KR20050105164A KR20050105164A KR1020057005830A KR20057005830A KR20050105164A KR 20050105164 A KR20050105164 A KR 20050105164A KR 1020057005830 A KR1020057005830 A KR 1020057005830A KR 20057005830 A KR20057005830 A KR 20057005830A KR 20050105164 A KR20050105164 A KR 20050105164A
- Authority
- KR
- South Korea
- Prior art keywords
- reaction
- hydroxybutyrate
- product
- agent
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000000047 product Substances 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 238000000746 purification Methods 0.000 claims abstract description 10
- 238000000926 separation method Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 24
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- -1 alkyl 4-cyano-3-hydroxybutyrate Chemical compound 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- LOQFROBMBSKWQY-UHFFFAOYSA-N ethyl 4-cyano-3-hydroxybutanoate Chemical compound CCOC(=O)CC(O)CC#N LOQFROBMBSKWQY-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 7
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012346 acetyl chloride Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- 238000007086 side reaction Methods 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- AIZRKZQHJNWBEI-UHFFFAOYSA-N ethyl 4-bromo-3-hydroxybutanoate Chemical compound CCOC(=O)CC(O)CBr AIZRKZQHJNWBEI-UHFFFAOYSA-N 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 150000001266 acyl halides Chemical class 0.000 claims 1
- 229910001508 alkali metal halide Inorganic materials 0.000 claims 1
- 150000008045 alkali metal halides Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical group N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 14
- FUDDLSHBRSNCBV-UHFFFAOYSA-N 4-hydroxyoxolan-2-one Chemical compound OC1COC(=O)C1 FUDDLSHBRSNCBV-UHFFFAOYSA-N 0.000 abstract description 9
- 239000000543 intermediate Substances 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 abstract description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 2
- 229940002661 lipitor Drugs 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000007142 ring opening reaction Methods 0.000 description 10
- FUDDLSHBRSNCBV-VKHMYHEASA-N (4s)-4-hydroxyoxolan-2-one Chemical compound O[C@@H]1COC(=O)C1 FUDDLSHBRSNCBV-VKHMYHEASA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- MKGMMNMIMLTXHO-ONEGZZNKSA-N ethyl (e)-4-hydroxybut-2-enoate Chemical compound CCOC(=O)\C=C\CO MKGMMNMIMLTXHO-ONEGZZNKSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007333 cyanation reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004508 fractional distillation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- RMQJECWPWQIIPW-OWOJBTEDSA-N 4-hydroxy-crotonic acid Chemical compound OC\C=C\C(O)=O RMQJECWPWQIIPW-OWOJBTEDSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910001513 alkali metal bromide Inorganic materials 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/16—Preparation of carboxylic acid nitriles by reaction of cyanides with lactones or compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 쉽게 이용가능한 3-하이드록시-γ-부티로락톤으로부터 출발하여 상업적으로 중요한 신테톤 ACHB의 개선된 합성에 관한 것이다. 이 반응은 중간체의 분리나 정제없이 단일 팟 방법을 사용한다. 이는 바람직하지 않은 부생성물을 최소화하며 상업적인 스케일로 쉽게 사용될 수 있는 시약 및 조건을 사용하는 종래 기술에 사용되는 방법에 비하여 이로운 것이다. 생성물은 높은 수득율로 얻어지며, L-카르니틴과 같은 상업적으로 중요한 생성물 및 Lipitor와 같은 HMG-coA 환원효소 억제제 생성물에 사용되는 약제학적으로 중요한 활성 물질의 추가 합성에 우수한 중간체를 제공하기 위해 쉽게 정제된다. The present invention is directed to improved synthesis of commercially important syntetone ACHBs starting from readily available 3-hydroxy-γ-butyrolactone. This reaction uses a single pot method without separation or purification of intermediates. This is advantageous over the methods used in the prior art, which use reagents and conditions that minimize undesirable byproducts and can easily be used on a commercial scale. The product is obtained in high yield and is easily purified to provide an excellent intermediate for further synthesis of pharmaceutically important active substances used in commercially important products such as L-carnitine and HMG-coA reductase inhibitor products such as Lipitor. .
Description
본 발명은 분리되지 않은 중간체 알킬 4-할로-3-하이드록시부티레이트, 바람직하게는 4-아이오도(AIHB) 또는 4-브로모(ABHB)를 거쳐 상업적으로 중요한 저급 알킬 4-시아노-3-하이드록시부티레이트(ACHB)의 신규한 원-팟(one-pot) 합성에 관한 것이다. 바람직한 구현에 있어서, 에틸 에스테르 EIHB 또는 EBHB가 사용된다. 상기 합성을 적용하여 광학 활성 또는 라세믹 생성물이 합성된다. 이는 원하는 최종 생성물을 고순도의 높은 수득율로 제공하며, 환경을 오염시키지 않으며 바람직하지 않은 부반응을 최소화하는 시약을 사용하여 상업적인 규모로 용이하게 수행된다. The present invention provides commercially important lower alkyl 4-cyano-3- via unisolated intermediate alkyl 4-halo-3-hydroxybutyrate, preferably 4-iodo (AIHB) or 4-bromo (ABHB). Novel one-pot synthesis of hydroxybutyrate (ACHB). In a preferred embodiment, ethyl ester EIHB or EBHB is used. The synthesis is applied to synthesize an optically active or racemic product. This is easily carried out on a commercial scale with reagents that provide the desired end product in high purity, high yields and do not pollute the environment and minimize undesirable side reactions.
에틸에스테르 ECHB 및 중간체 EIHB 및 EBHB는 알려진 화합물이며, 이는 종래에 보고된 합성 방법으로 제조되었다. 이에 따라, 예를 들어, Hollingsworth et al.,의 미국 특허 제 6,114,566에서는, (R)-ECHB(화합물 4)가 (S)-EBHB (5) 및 상응하는 비분리된 광학 활성 3,4-에폭시드 (6)을 거쳐 (S)-3-하이드록시-γ-부티로락톤(3)으로부터 출발하여 3단계로 제조한다. 제 1단계에서, 락톤 (3)은 아세트산에 용해된 30% 하이드로겐 브로마이드와 60℃로 4시간동안 반응시켰다. 에탄올을 가하고 반응 혼합물을 4~6시간동안 일정한 온도로 고정시켰다. 그 혼합물을 농축한 다음 중화시킨 후에 톨루엔으로 취하고, 농축하여 (S)-EBHB를 90%의 조질 수득율로 얻었다. 증류후에, 황색 오일의 생성물이 95% 이상의 순도로 시험되었다. Ethyl ester ECHB and intermediates EIHB and EBHB are known compounds, which have been prepared by conventionally reported synthetic methods. Thus, for example, in US Pat. No. 6,114,566 to Hollingsworth et al., (R) -ECHB (Compound 4) is a (S) -EBHB (5) and the corresponding non-isolated optically active 3,4-epoxy. Prepared in three steps starting from (S) -3-hydroxy-γ-butyrolactone (3) via de (6). In the first step, lactone (3) was reacted with 30% hydrogen bromide dissolved in acetic acid at 60 ° C. for 4 hours. Ethanol was added and the reaction mixture was held at a constant temperature for 4-6 hours. The mixture was concentrated and then neutralized and then taken up with toluene and concentrated to give (S) -EBHB at a crude yield of 90%. After distillation, the product of yellow oil was tested with at least 95% purity.
상기 (S)-EBHB 중간체 (5)는 50℃에서 수성 에탄올내의 NaCN으로 처리되었다. 용매를 회전 증발하여 워크업하고 에틸아세테이트로 추출하여 (R)-ECHB를 황색 오일로서 95%의 조질 수득율로 얻었으며, 이는 증류로 추가 정제되었다. 이 방법에서는 조질 수득율이 높지만, 상업적 스케일에 적용하기에는 부족하였다. 이에 따라, 아세트산에 용해된 30% HBr 용액의 이용가능성은 상업적 스케일에 있어서 제한되며, 아세트산의 사용으로 인해 워크업은 복잡해진다. Hollingsworth et al.,에 의해 사용되는 조건과 동일하게 수행하는 경우에, 원하지 않은 부생성물 에틸 4-하이드록시크로토네이트가 3 내지 10%의 수득율로 형성되었다. 에스테르계 생성물을 그 상응하는 산으로 시안화 단계 도중에 가수분해하는 도중에 다른 문제가 발생하였다. 또한, 낮은 수율의 에틸 4-하이드록시크로토네이트가 생성되는 경우에, 상응하는 가수분해 양이 증가됨이 관찰되었다. The (S) -EBHB intermediate (5) was treated with NaCN in aqueous ethanol at 50 ° C. The solvent was worked up by rotary evaporation and extracted with ethyl acetate to give (R) -ECHB as a yellow oil with a crude yield of 95%, which was further purified by distillation. The crude yield was high in this method, but it was insufficient for commercial scale. As such, the availability of 30% HBr solutions dissolved in acetic acid is limited on a commercial scale and the work up is complicated by the use of acetic acid. When carried out under the same conditions as used by Hollingsworth et al., The unwanted byproduct ethyl 4-hydroxycrotonate was formed at a yield of 3-10%. Another problem arose during the hydrolysis of the ester-based product with its corresponding acid during the cyanation step. It was also observed that when a low yield of ethyl 4-hydroxycrotonate is produced, the corresponding amount of hydrolysis is increased.
추가로, 고리 열림 시약으로서 TMSCl/NaI/CH2Cl2를 사용하는 경우가, Tetrahedron Letters, 28(16), 1781-1782(1987)(Larcheveque, M. and Henrot, S.), Tetrahedron, 46(12), 4277~4282(1990)(Larcheveque, M. and Henrot, S.) 및 WO9306826에 추가로 개시되어 있다. Larcheveque 및 Henrot이 보고한 바에 따르면, (S)-3-하이드록시부티로락톤의 고리열림은 상이한 조건에서 진행되며 아이오도히드린 생성물, (S)-에틸-3-하이드록시-4-아이오도부티레이트가 얻어졌다. 이들은 여러가지 목적의 트리메틸실릴 아이오다이드의 사용으로, 아이오도히드린을 중간정도의 수득율로 얻었다. 그러나, 이러한 방법을 대형 스케일에 적용할시에는 여러가지 문제가 발생한다. 즉, TMSI는 고가이며 매우 반응성이기 때문에 취급하기가 어렵다. G. Olah(Tetrahedron, 1982, 38, 2225-2227)와 같은 다른 공개물에서도, 일반적으로 이러한 종류의 반응이 다양한 부반응을 일으키며 정제 공정이 복잡한 것으로 알려져 있다. In addition, the use of TMSCl / NaI / CH2Cl2 as ring opening reagents is described in Tetrahedron Letters, 28 (16), 1781-1782 (1987) (Larcheveque, M. and Henrot, S.), Tetrahedron, 46 (12) , 4277-4282 (1990) (Larcheveque, M. and Henrot, S.) and WO9306826. As reported by Larcheveque and Henrot, the ring opening of (S) -3-hydroxybutyrolactone proceeds at different conditions and the iodohydrin product, (S) -ethyl-3-hydroxy-4-iodo Butyrate was obtained. These obtained trimethylsilyl iodide for various purposes, and obtained iodohydrin in moderate yield. However, various problems arise when applying this method to large scales. That is, TMSI is difficult to handle because it is expensive and very reactive. In other publications such as G. Olah (Tetrahedron, 1982, 38, 2225-2227), this kind of reaction is generally known to cause various side reactions and the purification process is complex.
본 발명은 쉽게 이용가능한 3-하이드록시-γ-부티로락톤으로부터 출발하여 상업적으로 중요한 신테톤(syntheton) ACHB의 개선된 합성에 관한 것이다. 이 반응은 중간체의 분리나 정제없이 싱글팟(single pot) 방법을 사용한다. 이는 바람직하지 않은 부생성물을 최소화하며 상업적인 스케일로 쉽게 사용될 수 있는 시약 및 조건을 사용하기 때문에 종래 기술에 사용되는 방법과 비교하여 이로운 것이다. 생성물은 높은 수득율로 얻어지며, L-카르니틴과 같은 상업적으로 중요한 제품 및 Lipitor®(Atorvastatin, Pfizer)와 같은 HMG-coA 환원효소 억제제 생성물에 사용되는 약제학적으로 중요한 활성 물질의 추가 합성을 위한 우수한 중간체를 제공하기 위해 용이하게 정제된다. The present invention is directed to an improved synthesis of commercially important syntheton ACHBs starting from the readily available 3-hydroxy-γ-butyrolactone. This reaction uses a single pot method without the isolation or purification of intermediates. This is advantageous compared to the methods used in the prior art because it minimizes undesirable byproducts and uses reagents and conditions that can easily be used on a commercial scale. The product is obtained in high yield and is an excellent intermediate for further synthesis of pharmaceutically important active substances used in commercially important products such as L-carnitine and HMG-coA reductase inhibitor products such as Lipitor® (Atorvastatin, Pfizer). It is easily purified to provide.
본 발명의 방법에 따른 제 1단계에서, 라세믹 또는 광학활성 형태로, 출발물질 3-하이드록시-γ부티로락톤을 할라이드제를 사용하여 고리열림 반응에 적용시킨다. 이 반응은 아실화제 및 저급 알칸올의 존재하에서 수행되는 경우에 빠르고, 깨끗하고 양적인 수득율로 얻어진다. 적합한 할라이드제로는 브롬 또는 요오드를 제공하는 시약을 포함하며, 이러한 시약으로는 예를 들어, 용액 또는 가스 형태의 하이드로겐 브로마이드, 하이드로겐 아이오다이드, 트리메틸실릴 브로마이드 또는 아이오다이드, 또는 바람직하게 염산, 황산등과 같은 미네랄 산의 존재하에서 소디움 브로마이드와 같은 알칼리 금속 브로마이드 또는 아이오다이드를 포함한다. 적합한 아실화제로는 아세틸클로라이드 또는 아세틸 브로마이드와 같은 저급 알카노일 할라이드, 아세트산 무수물과 같은 알카노익 무수물, 저급 지방족 카르복시산의 에틸에스테르와 같은 저급 알킬 알카노에이트, 가장 바람직하게는 에틸 아세테이트 또는 에틸 포르메이트 및 이들의 혼합물을 포함한다. 본 발명에서 사용되는 용어 "저급"이란, 1 내지 4개의 탄소원자를 갖는 부분을 의미한다. 본 발명의 실시에 유용한 선택적인 시약으로는, 모든 작용성을 제공하는 저급 알카노일 브로마이드를 포함한다. 바람직한 저급 알카노일 브로마이드는 아세틸 브로마이드이다. 이 반응에서는 바람직하지 않은 부반응을 회피하기 위해 아세트산의 존재하에서 하이드로겐 브로마이드의 사용을 피하는 것이 가장 바람직하다. In a first step according to the process of the invention, in racemic or optically active form, the starting material 3-hydroxy-γbutyrolactone is subjected to a ring opening reaction using a halide agent. This reaction is obtained in fast, clean and quantitative yields when carried out in the presence of acylating agents and lower alkanols. Suitable halide agents include reagents that provide bromine or iodine, such reagents, for example, hydrogen bromide, hydrogen iodide, trimethylsilyl bromide or iodide in solution or gas form, or preferably hydrochloric acid Alkali metal bromide or iodide such as sodium bromide in the presence of mineral acids such as sulfuric acid, and the like. Suitable acylating agents include lower alkanoyl halides such as acetylchloride or acetyl bromide, alkanoic anhydrides such as acetic anhydride, lower alkyl alkanoates such as ethyl esters of lower aliphatic carboxylic acids, most preferably ethyl acetate or ethyl formate And mixtures thereof. As used herein, the term "lower" means a moiety having from 1 to 4 carbon atoms. Optional reagents useful in the practice of the present invention include lower alkanoyl bromide that provides all functionality. Preferred lower alkanoyl bromide is acetyl bromide. In this reaction, it is most desirable to avoid the use of hydrogen bromide in the presence of acetic acid in order to avoid undesirable side reactions.
제 1단계는 이러한 조건이 매우 제한적이지 않은 어떠한 통상적인 반응 조건으로 수행될 수 있다. 적합한 반응 온도는 0 내지 100℃의 범위일 수 있다. 바람직한 온도의 범위는 50 내지 60℃이다. 고리열림 반응 이후에, 생성된 카르복시산은 저급 알칸올, 가장 바람직하게는 에탄올과 같은 알킬화제의 존재하에서 에스테르화되어 원하는 중간 생성물 AIHB 또는 ABHB를 제공한다. 아실화제 및 저급 알킬은 모두 상기 반응의 용매로 제공되도록 다른 반응물의 당량몰 양 이상으로 존재한다. The first step can be carried out under any conventional reaction conditions, such conditions are not very limited. Suitable reaction temperatures may range from 0 to 100 ° C. Preferable temperature range is 50-60 degreeC. After the ring opening reaction, the resulting carboxylic acid is esterified in the presence of an alkylating agent such as a lower alkanol, most preferably ethanol to give the desired intermediate product AIHB or ABHB. Both the acylating agent and lower alkyl are present in at least the equivalent molar amount of the other reactants to serve as the solvent of the reaction.
상기 제 1단계 반응은 하이드로겐 클로라이드, 소디움 클로라이드/하이드로겐 클로라이드 또는 트리메틸실릴 클로라이드와 같은 염소화제를 이용하는 경우에 성곡적으로 수행되지 않음을 참고해야 한다. Note that the first step reaction is not performed successfully when using a chlorinating agent such as hydrogen chloride, sodium chloride / hydrogen chloride or trimethylsilyl chloride.
원하는 고리열림 반응은 다음 단계에서 분리 및 정제의 필요없이 중간체를 바로 사용하도록 정량적인 조절 수득율 및 순도로 AIHB 또는 ABHB를 생성하도록 본 발명의 방법에 따라 수행된다. The desired ring opening reaction is carried out in accordance with the process of the present invention to produce AIHB or ABHB in quantitative controlled yield and purity to use the intermediate directly without the need for separation and purification in the next step.
본 발명의 제 2단계에서, 조질의, 분리되지 않은 제 1단계에서 얻어진 AIHB 또는 ABHB 생성물을 시아니드 이온의 공급원과 반응하여 원하는 생성물 ACHB, 가장 바람직하게는 에틸에스테르로서(ECHB)가 얻어진다. 이러한 반응단계의 적합한 시아니드 이온 공급원은 알칼리 금속 시아니드, 가장 바람직하게는, 소디움 또는 포타슘 시아니드이다. 시안화 반응은 상기 제 1단계에서 사용되는 동일한 용매를 사용하여 수행되며, 즉, 에탄올과 같은 저급 알칸올이 수성 혼합물(에탄올 대 물의 비율 1:10 내지 10:1)에 존재할 수 있다. 본 발명의 제 1단계에서와 같이, 사용되는 온도 조건은 제한되지 않는다. 그러나, AIHB 또는 ABHB 중간체에 시아니드 시약을 첨가하여 생성되는 발열반응으로 인해, 반응을 약 25℃의 온도에서 개시하고 냉각에 의해 대략 수준이하로 온도를 유지하는 것이 바람직하다. 시아니드 이온 시약의 첨가 완료 후에, 반응 혼합물은 1 내지 24시간동안, 가장 바람직하게는 약 6시간동안 약 35℃의 온도에서 가열될 수 있다. In a second step of the invention, the AIHB or ABHB product obtained in the crude, unseparated first step is reacted with a source of cyanide ions to give the desired product ACHB, most preferably as ethyl ester (ECHB). Suitable cyanide ion sources in this reaction step are alkali metal cyanide, most preferably sodium or potassium cyanide. The cyanation reaction is carried out using the same solvent used in the first step, ie lower alkanols such as ethanol can be present in the aqueous mixture (ethanol to water ratio of 1:10 to 10: 1). As in the first step of the invention, the temperature conditions used are not limited. However, due to the exothermic reaction produced by the addition of cyanide reagents to the AIHB or ABHB intermediates, it is desirable to initiate the reaction at a temperature of about 25 ° C. and maintain the temperature below approximately levels by cooling. After completion of the cyanide ion reagent addition, the reaction mixture may be heated at a temperature of about 35 ° C. for 1 to 24 hours, most preferably about 6 hours.
반응 혼합물의 pH는 7 내지 11, 바람직하게는 7.5 내지 10.5, 가장 바람직하게는 8 내지 9.5의 범위가 바람직하다. 필요에 따라, 하이드로겐 아이오다이드 또는 하이드로겐 브로마이드와 같은 하이드로겐 할라이드를 가하여 pH 조절을 효과적으로 할 수 있다. 이러한 방법으로 반응을 수행함으로써, 시아니드 이온과의 반응이 강염기 조건하에서 물에 EBHB와 수행되거나 또는 물/알콜 혼합물(에틸 4-하이드록시크로토네이트 형성 및 에스테르의 가수분해)이 실질적으로 환원되거나 또는 함께 제거되는 경우에 부반응이 발생함을 예상치 못하게 발견하였다. 반대로, 종래기술의 수성 조건이 사용되는 경우, 3 내지 10%의 부생성물 에틸 4-하이드록시크로토네이트가 관찰되었으며, 본 발명의 조건이 사용되는 경우에 GC 피크에 의해 전체 <2%의 에틸-4-하이드록시크로토네이트가 관찰된다. 또한, 이는 검출할 수 없는 수준의 가수분해물이다.The pH of the reaction mixture is preferably in the range of 7 to 11, preferably 7.5 to 10.5, most preferably 8 to 9.5. If necessary, the pH can be effectively adjusted by adding a hydrogen halide such as hydrogen iodide or hydrogen bromide. By carrying out the reaction in this way, the reaction with cyanide ions is carried out with EBHB in water under strong base conditions or the water / alcohol mixture (ethyl 4-hydroxycrotonate formation and hydrolysis of esters) is substantially reduced or Or it was unexpectedly found that side reactions occur when they are removed together. Conversely, when the aqueous conditions of the prior art were used, 3 to 10% of byproduct ethyl 4-hydroxycrotonate was observed, with total <2% ethyl by GC peak when the conditions of the invention were used. 4-hydroxycrotonate is observed. It is also an undetectable level of hydrolyzate.
그 다음 상기 반응 혼합물을 적합한 유기 용매 또는 용매 혼합물로 추출 및 반응용매를 농축하여 통상적인 방법으로 워크업할 수 있다. 최종 생성물은 배치 또는 연속 모드로 진공 프랙션 증류에 의해 정제되어 상업적인 스케일, 약학적으로 중요한 중요한 최종 생성물의 약제학적 제조에 사용하기 적합한 높은 수득율 및 순도로 원하는 CHB가 제공된다. The reaction mixture can then be extracted with a suitable organic solvent or solvent mixture and the reaction solvent can be concentrated up in a conventional manner. The final product is purified by vacuum fractional distillation in batch or continuous mode to provide the desired CHB in high yield and purity suitable for use in commercial scale, pharmaceutical preparation of pharmaceutically important important end products.
이하 실시예를 통하여 본 발명을 보다 상세히 설명하고자 하며 이로써 본 발명을 제한하는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to the following examples, which do not limit the present invention.
실시예 1Example 1
(A) 고리열림 시약으로서 하이드로겐 브로마이드/아세틸 클로라이드/에틸 아세테이트/에탄올을 사용(A) Hydrogen bromide / acetyl chloride / ethyl acetate / ethanol as ring opening reagent
10g의 (S)-3-하이드록시-γ-부티로락톤 및 50ml의 에틸 아세테이트의 혼합물을 0℃로 냉각하였다. 교반과 함께, 7.7g의 아세틸클로라이드를 천천히 첨가하였다. 에탄올에 6N HBr 총 50ml(50ml EtOH 및 24g(3eq)HBr))를 첨가하고 혼합물을 최대 50℃로 승온시키고 3시간동안 그 온도에서 유지하였다. 상기 혼합물을 농축하여 대부분의 에틸 아세테이트를 제거하였다. 에탄올, 50ml,를 잔류물에 첨가하고 결과 용액을 5시간동안 50℃에서 교반하였다. 상기 혼합물을 농축하여 대부분의 용매를 제거하였다. 결과 생성물은 약간 황색을 띠는 오일이며 정량적인 수득율로 얻었다. 그러나, 추가의 분리 또는 정제없이 다음 단계에 바로 사용된다. A mixture of 10 g of (S) -3-hydroxy-γ-butyrolactone and 50 ml of ethyl acetate was cooled to 0 ° C. With stirring, 7.7 g of acetylchloride was slowly added. To the ethanol was added 50 ml total of 6N HBr (50 ml EtOH and 24 g (3 eq) HBr) and the mixture was warmed up to 50 ° C. and kept at that temperature for 3 hours. The mixture was concentrated to remove most ethyl acetate. Ethanol, 50 ml, was added to the residue and the resulting solution was stirred at 50 ° C. for 5 hours. The mixture was concentrated to remove most solvent. The resulting product was a slightly yellowish oil and obtained in quantitative yield. However, it is used directly in the next step without further separation or purification.
(B) 고리열림 시약으로서 하이드로겐 브로마이드/에틸아세테이트/에탄올을 사용(B) using hydrogen bromide / ethyl acetate / ethanol as ring opening reagent
10g의 (S)-3-하이드록시-γ-부티로락톤 및 50ml의 에틸 아세테이트의 혼합물에 에탄올에 6N HBr 총 50ml(50ml EtOH 및 24g(3eq)HBr))를 첨가하였다. 혼합물을 최대 50℃로 승온시키고 5시간동안 그 온도에서 유지하였다. 상기 혼합물을 농축하여 대부분의 에틸 아세테이트를 제거하였다. 에탄올, 50ml,를 잔류물에 첨가하고 결과 용액을 5시간동안 50℃에서 교반하였다. 상기 혼합물을 농축하여 대부분의 용매를 제거하였다. 결과 생성물은 약간 황색을 띠는 오일이며 정량적인 수득율로 얻었다. 그러나, 추가의 분리 또는 정제없이 다음 단계에 바로 사용된다. To a mixture of 10 g of (S) -3-hydroxy-γ-butyrolactone and 50 ml of ethyl acetate was added 50 ml (50 ml EtOH and 24 g (3 eq) HBr) total of 6N HBr to ethanol. The mixture was warmed up to 50 ° C. and kept at that temperature for 5 hours. The mixture was concentrated to remove most ethyl acetate. Ethanol, 50 ml, was added to the residue and the resulting solution was stirred at 50 ° C. for 5 hours. The mixture was concentrated to remove most solvent. The resulting product was a slightly yellowish oil and obtained in quantitative yield. However, it is used directly in the next step without further separation or purification.
(C) 고리열림 시약으로서 아세트산 무수물/에틸 아세테이트/에탄올/하이드로겐 브로마이드를 사용(C) Use of acetic anhydride / ethyl acetate / ethanol / hydrogen bromide as ring opening reagent
10g의 (S)-3-하이드록시-γ-부티로락톤, 9.2ml의 아세트산 무수물 및 50ml의 에틸 아세테이트의 혼합물에 에탄올에 6N HBr 총 50ml(50ml EtOH 및 24g(3eq)HBr))를 첨가하고 상기 혼합물을 최대 50℃로 승온시키고 3시간동안 그 온도에서 유지하였다. 상기 혼합물을 농축하여 대부분의 에틸 아세테이트를 제거하였다. 에탄올, 50ml,를 잔류물에 첨가하고 결과 용액을 5시간동안 50℃에서 교반하였다. 상기 혼합물을 농축하여 대부분의 용매를 제거하였다. 결과 생성물은 약간 황색을 띠는 오일이며 정량적인 수득율로 얻었다. 그러나, 추가의 분리 또는 정제없이 다음 단계에 바로 사용될 수 있다. To a mixture of 10 g of (S) -3-hydroxy-γ-butyrolactone, 9.2 ml of acetic anhydride and 50 ml of ethyl acetate, 50 ml of total 6N HBr (50 ml EtOH and 24 g (3 eq) HBr)) were added to ethanol. The mixture was warmed up to 50 ° C. and maintained at that temperature for 3 hours. The mixture was concentrated to remove most ethyl acetate. Ethanol, 50 ml, was added to the residue and the resulting solution was stirred at 50 ° C. for 5 hours. The mixture was concentrated to remove most solvent. The resulting product was a slightly yellowish oil and obtained in quantitative yield. However, it can be used directly in the next step without further separation or purification.
(D) 고리 열림 시약으로서 아세틸 클로라이드/에틸아세테이트/에탄올/소디움 브로마이드를 사용(D) using acetyl chloride / ethyl acetate / ethanol / sodium bromide as ring opening reagent
10g의 (S)-3-하이드록시-γ-부티로락톤 및 50ml의 에틸 아세테이트의 혼합물을 0℃로 냉각하였다. 교반과 함께, 7.7g의 아세틸클로라이드를 천천히 첨가하였다. 에탄올에 6N HBr 총 50ml(50ml EtOH 및 24g(3eq)HBr))를 첨가하고 혼합물을 최대 50℃로 승온시키고 3시간동안 그 온도에서 유지하였다. 상기 혼합물을 농축하여 대부분의 에틸 아세테이트를 제거하였다. 에탄올, 50ml,를 잔류물에 첨가하고 결과 용액을 48시간동안 50℃에서 교반하였다. 상기 혼합물을 농축하여 대부분의 용매를 제거하였다. 결과 생성물은 약간 황색을 띠는 오일이며 정량적인 수득율로 얻었다. 그러나, 추가의 분리 또는 정제없이 다음 단계에 바로 사용될 수 있다. A mixture of 10 g of (S) -3-hydroxy-γ-butyrolactone and 50 ml of ethyl acetate was cooled to 0 ° C. With stirring, 7.7 g of acetylchloride was slowly added. To the ethanol was added 50 ml total of 6N HBr (50 ml EtOH and 24 g (3 eq) HBr) and the mixture was warmed up to 50 ° C. and kept at that temperature for 3 hours. The mixture was concentrated to remove most ethyl acetate. Ethanol, 50 ml, was added to the residue and the resulting solution was stirred at 50 ° C. for 48 h. The mixture was concentrated to remove most solvent. The resulting product was a slightly yellowish oil and obtained in quantitative yield. However, it can be used directly in the next step without further separation or purification.
(E) 고리열림 시약으로서 아세틸 브로마이드/에탄올을 사용(E) Acetyl bromide / ethanol as ring opening reagent
100g의 (S)-3-하이드록시-γ-부티로락톤, 136g의 에탄올 및 400ml의 에틸 아세테이트의 혼합물을 0℃로 냉각하였다. 교반과 함께, 241g의 아세틸브로마이드를 천천히 첨가하였다. 상기 혼합물을 50℃로 승온시키고 5시간동안 그 온도에서 유지하였다. 상기 혼합물을 농축하여 대부분의 에틸 아세테이트를 제거하였다. 에탄올, 400ml,를 잔류물에 첨가하고 결과용액을 5시간동안 50℃에서 교반하였다. 결과 생성물은 약간 황색을 띠며 실시예 2와 같이 분리 또는 추가의 정제없이 다음 단계에 서 바로 농축되거나 또는 사용될 수 있다. 수득율은은 정량적이었다. A mixture of 100 g of (S) -3-hydroxy-γ-butyrolactone, 136 g of ethanol and 400 ml of ethyl acetate was cooled to 0 ° C. With stirring, 241 g of acetylbromide was added slowly. The mixture was warmed to 50 ° C. and kept at that temperature for 5 hours. The mixture was concentrated to remove most ethyl acetate. Ethanol, 400 ml, was added to the residue and the resulting solution was stirred at 50 ° C. for 5 hours. The resulting product is slightly yellowish and can be concentrated or used directly in the next step without separation or further purification as in Example 2. Yield was quantitative.
실시예 2Example 2
(A) 에틸 4-시아노-3-하이드록시부티레이트(ECHB) 제조를 위한 원-팟 방법(A) One-pot method for the preparation of ethyl 4-cyano-3-hydroxybutyrate (ECHB)
실시예 1에서 얻어지는 용액에((S)-3-하이드록시GBL 20g에서 출발) NaCN의 용액을 첨가하였다(필요에 따라 HBr 또는 HCl와 같은 추가의 미네랄산을 첨가하여 pH를 8~9.5로 조절할 수 있다).To the solution obtained in Example 1 (starting at 20 g of (S) -3-hydroxyGBL), a solution of NaCN was added (addition of additional mineral acid, such as HBr or HCl, if necessary) to adjust the pH to 8-9.5. Can be).
이로부터 용액을 25℃로 냉각하였다. 물 40ml에 용해된 NaCN 22.6g의 용액을 20분동안 첨가하였다. 반응 온도를 첨가도중에 25℃로 유지하였다. 첨가 후에, 상기 반응 혼합물을 1시간동안 25℃에서 교반하였다. 상기 반응을 6시간동안 35℃로 승온시켰다. 상기 용액을 25℃로 냉각시키고 100ml의 메틸렌 클로라이드로 2회 추출하였다. 농축 후에, 33g의 조질 에틸 4-시아노-3-하이드록시부티레이트가 얻어졌다. 정량 GC에 의해 분석된 수득율은 생성물 수득율이 평균 >80% 이다.From this the solution was cooled to 25 ° C. A solution of 22.6 g of NaCN dissolved in 40 ml of water was added for 20 minutes. The reaction temperature was maintained at 25 ° C. during the addition. After addition, the reaction mixture was stirred at 25 ° C. for 1 hour. The reaction was heated to 35 ° C. for 6 hours. The solution was cooled to 25 ° C. and extracted twice with 100 ml of methylene chloride. After concentration, 33 g of crude ethyl 4-cyano-3-hydroxybutyrate was obtained. Yields analyzed by quantitative GC have an average product yield of> 80%.
R 형태의, ECHB 생성물은 진공 프랙션 증류에 의해 배치 또는 연속 모드로 추가 정제되었다. 증류 회수율은 >95% 이다. b.p. 270℃(116℃/0.8mmHg)The ECHB product, in R form, was further purified in batch or continuous mode by vacuum fractional distillation. Distillation recovery is> 95%. b.p. 270 ° C (116 ° C / 0.8mmHg)
% e.e.>98%(GC에 의해, 락톤 출발물질의 광학 순도는 유지됨)% e.e.> 98% (by GC, the optical purity of the lactone starting material is maintained)
본 발명의 특정한 구현에 대하여 기술한 상기한 바로부터, 다양한 변형, 조절 및 개선은 이 기술분야의 기술자에게 쉽게 이해될 수 있을 것이다. 이러한 변형, 조절 및 개선 모두는 본 발명의 범주에 속하는 것으로 이해된다. 따라서, 상기한 사항은 단지 본 발명을 예시하는 것으로 이로써 본 발명을 제한하는 것은 아니다. From the foregoing description of particular implementations of the invention, various modifications, adjustments and improvements will be readily apparent to those skilled in the art. It is understood that all such modifications, adjustments and improvements fall within the scope of the present invention. Accordingly, the foregoing is merely illustrative of the present invention, which does not limit the present invention.
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41567202P | 2002-10-03 | 2002-10-03 | |
US60/415,672 | 2002-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050105164A true KR20050105164A (en) | 2005-11-03 |
Family
ID=32069896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057005830A Ceased KR20050105164A (en) | 2002-10-03 | 2003-09-30 | Improved syntheton sythesis |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1551796A4 (en) |
JP (1) | JP2006502201A (en) |
KR (1) | KR20050105164A (en) |
CN (1) | CN1688539A (en) |
AU (1) | AU2003272793A1 (en) |
CA (1) | CA2500668A1 (en) |
WO (1) | WO2004031131A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114566A (en) * | 1999-05-24 | 2000-09-05 | Board Of Trustees Operating Michigan State University | 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof |
-
2003
- 2003-09-30 WO PCT/US2003/030869 patent/WO2004031131A1/en not_active Application Discontinuation
- 2003-09-30 JP JP2004541917A patent/JP2006502201A/en active Pending
- 2003-09-30 EP EP03754994A patent/EP1551796A4/en not_active Withdrawn
- 2003-09-30 AU AU2003272793A patent/AU2003272793A1/en not_active Abandoned
- 2003-09-30 CN CNA038235366A patent/CN1688539A/en active Pending
- 2003-09-30 CA CA002500668A patent/CA2500668A1/en not_active Abandoned
- 2003-09-30 KR KR1020057005830A patent/KR20050105164A/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1551796A1 (en) | 2005-07-13 |
EP1551796A4 (en) | 2007-03-14 |
CN1688539A (en) | 2005-10-26 |
JP2006502201A (en) | 2006-01-19 |
WO2004031131A1 (en) | 2004-04-15 |
AU2003272793A1 (en) | 2004-04-23 |
CA2500668A1 (en) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040068141A1 (en) | Process for the synthesis of trifluorophenylacetic acids | |
KR20060118483A (en) | How to Make Vitamin B6 | |
KR101886643B1 (en) | Process for the Preparation of Lacosamide | |
JP3675274B2 (en) | Method for producing 9- (2-hydroxyalkyl) purine derivative and 1- (2-hydroxyalkyl) pyrimidine derivative | |
US6278002B1 (en) | Process for the preparation of (2r,3s)-3-amino-1,2-oxirane | |
Donohoe et al. | The stereoselective Birch reduction of pyrroles | |
US6365754B1 (en) | Process for producing erythro-3-amino-2-hydroxybutyric acid derivatives | |
KR20050105164A (en) | Improved syntheton sythesis | |
EP0640579B1 (en) | Process for producing optically active 2-norbornanone | |
KR100369274B1 (en) | Improved process for producing 4-hydroxy-2-pyrrolidone | |
EP0339618B1 (en) | Method for preparing optically active 3,4-dihydroxy butyric acid derivatives | |
KR100332703B1 (en) | Method for preparing (S) -3,4-epoxybutyrate having optical activity | |
US6175024B1 (en) | Synthesis of functionalized esters | |
KR100322630B1 (en) | Processes for Producing Simvastatin and its Intermediate | |
US2459059A (en) | Method for preparing alkyl acyloxy acrylates | |
JP2000229930A (en) | Production of cyanoacetate ester | |
JP3272377B2 (en) | Optical resolution of optically active glutaric acid ester derivatives | |
JP2974181B2 (en) | A new method for producing cyclobutanol | |
KR20070048741A (en) | Method for preparing diarylcycloalkyl derivative | |
KR100445781B1 (en) | Process for preparing (S)-1-acetyl-2-pyrrolidinecarboxamide | |
JP2720934B2 (en) | Process for producing 3- (2-chloro-2- (4-chlorophenyl) -vinyl) -2,2-dimethylcyclopropanecarboxylic acid | |
US6414181B1 (en) | Process of producing cyclopropanecarboxylate compounds | |
US20030060666A1 (en) | Process for the preparation of alpha-haloketones | |
JP2001278839A (en) | Method for producing optically active carboxylic acid having substituent at 2-position | |
JPH1171325A (en) | Method for producing alkyl 4-arylbutanoates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20050404 Patent event code: PA01051R01D Comment text: International Patent Application |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050708 Comment text: Request for Examination of Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060921 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20061201 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060921 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |